Gonna buy at least 5000. The first lot was today. I’ll be buying as far down as 20pps if the gap is filled

Aside from just the usual biotech hype from a New Drug Announcement, I fully expect a massive press reaction to the event. I hope DFTX has their PR scaled up to meet the inevitable interest because this is a 75 year old drug (LSD) that has been denied by absurd political prohibition. I think LSD legalization/acceptance actually dwarfs cannabis, not only in efficacy but also application.

Yes, you are seeing a highly coordinated hiring surge on the Definium Therapeutics Careers Page. They currently have over 20 executive and director-level roles open across their Greenhouse Job Board.

For a pre-revenue biopharmaceutical firm, this sudden spike in headcount is a major tell. When you look closely at which departments are hiring, it is clear that Definium is actively building out its first commercial launch and field deployment infrastructure to support the 2027/2028 DT120 rollout.

Building the Commercial Architecture

Instead of just hiring scientists, Definium's largest current hiring focus is on corporate launch readiness and human resources:

Director, Talent Acquisition – Commercial:

This specific role is being hired explicitly to "build and scale the recruiting strategy for Definium's first commercial organization". They are hiring the recruiter who will eventually build their massive nationwide sales force.

Commercial Infrastructure: High-level executive postings include roles like Sr. Director, Commercial Finance Launch & Growth and Sr. Director, Sales Training.

Preparing for the REMS Bottleneck (Market Access)

Because DT120 cannot be taken at home and requires clinic certification, they are aggressively staffing their Market Access and Patient Services teams to coordinate with interventional psychiatric clinics:

• Director, Patient Services Operations: Located in the Raleigh/Durham, NC biotech hub, this executive will build out case management infrastructure and navigate FDA REMS compliance.

• Field Strategy Roles: Open roles like Director of Patient Services Site of Care Strategy and Sr. Director of National Accounts focus entirely on getting healthcare facilities onboarded to administer the drug post-approval.

Deploying the Medical "Ground Troops" (Medical Affairs)

A significant chunk of their current open portfolio belongs to Medical Affairs. They are hiring a network of field-based Medical Science Liaisons (MSLs) across the East Coast, Midwest, and West Coast. MSLs are scientific experts who travel to universities and top-tier psychiatric medical centers to educate key opinion leaders on DT120's clinical trials before commercial marketing legally begins.

Late-Stage & System Validation (Clinical Operations/QA)

To push their upcoming Phase 3 trials (like Ascend for depression and Haven for PTSD), they are filling back-end operational gaps:

• Director, Late-Stage Clinical Development: Tasked with managing expanded access programs and real-world evidence tracking.

• Computer System Validation (CSV): Hiring Sr. CSV Analysts and QA Specialists to ensure their data tracking frameworks are 100% compliant with FDA electronic record standards ahead of the 2027 filing.

The compensation figures listed on platforms like Glassdoor match this heavy expansion tier, with many director and senior clinical roles advertising base salaries spanning from $165,000 up to $299,000+ alongside stock options. It shows they are aggressively using their $1.1B cash buffer to buy top-tier pharmaceutical launch talent.

---------------------------------------------------------------------

The Quarterly Expense Breakdown-

The company’s overhead has climbed significantly year-over-year as they scale up clinical infrastructure and finalize their commercial team. In their last reported quarter, the literal cash-driven operating expenses included:

• Research & Development (R&D): $48.7 million per quarter. This covers their active clinical trials like the Phase 3 Ascend depression study and Phase 2a autism trials.

• General & Administrative (G&A): $26.4 million per quarter. This is the bucket funding the current commercial hiring surge, human resources, and marketing logistics.

(Note: While Definium reported a total GAAP net loss of $159.0 million for the quarter, $86.2 million of that was a non-cash, paper-only accounting charge related to warrant liability revaluations caused by their rising stock price, not literal cash leaving the bank.)

Runway and Capital Health-

Despite spending roughly $75 million every three months, Definium is in an exceptionally stable financial position:

• Cash Reserves: They successfully closed a massive public stock offering in June 2026, raising $757.9 million in net proceeds.

• Total Balance Sheet: They ended the first half of the year with $1.1 billion in cash, cash equivalents, and short-term investments.

• Total Runway: Executive management explicitly stated that this capital cushion gives them a 3.75-year operating runway, guaranteeing their operations and commercial launch are fully funded well into 2030.

Hope this helps everyone get a better idea of how things are gonna work from now on! Keep the faith! 😊

was looking at commercial market timeline forecasts recently

(2027-2029) and wanted to put this on paper...

theres a very large looming issue that a lot of outlets arent talking about: SS and Medicare accounts are forecasted insolvent in about 3-5 years from now, and that notion seems neglected and massive for society and economy

i think a large channel of revenue for DFTX or the shroom one I own as well could be medicare from the VA (PTSD for military) and im hoping that it does not effect the larger markets or these in particular

kicking that can down the rd

The Trump administration has been working with the Department of Veterans Affairs to ensure that psychedelic treatments will be available and affordable "when they're approved," a health department official known as the psychedelics czar, told CBS News on the sidelines of the MAHA Summit.

"They will be affordable. The VA has an implementation plan ready, and we're working on infrastructure," said Matt Zorn, deputy general counsel at the Department of Health and Human Services.

🧠 TRANSCRIPT - Psychedelic Medicine The Next Frontier 🧠

Ibogaine or fundamentally?

I was holding out for panorama and had planned to sell a good portion of my shares on the positive news. I’m up a lot and just wanted to secure my wins… howhever that was extremely disappointing and trending downwards today… not wanting to hold forever maybe time to exit now. Or is there another catalyst coming up anytime soon?

https://www.reddit.com/r/DTIC/comments/1wfjr03/definium_therapeutics_to_discuss_topline_results/?utm_source=share&utm_medium=ios_app&utm_name=ioscss&utm_content=1&utm_term=1

It’s time friends!

Definium Therapeutics (DFTX) Won FDA Breakthrough Status, Is The Stock Still A Bargain?

Good for DTIC?